| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.67, 0.95] | | < 1 | | 0% | 3 studies (3/-) | 99.5 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.55 [0.46, 0.64] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 3.23 [0.69, 15.19] | | > 1 | | 92% | 3 studies (3/-) | 93.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.03 [0.18, 23.06] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 2.44 [1.17, 5.12] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 4.10 [0.18, 92.93] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.58 [1.16, 5.75] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.68 [0.48, 0.96] | | < 1 | | 0% | 3 studies (3/-) | 98.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.92 [0.29, 2.85] | | < 1 | | 91% | 3 studies (3/-) | 56.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.62 [0.21, 12.60] | | < 1 | | 0% | 3 studies (3/-) | 32.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.62 [0.86, 3.05] | | < 1 | | 36% | 3 studies (3/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.06 [0.87, 4.87] | | < 1 | | 0% | 2 studies (2/-) | 5.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.08 [0.01, 0.43] | | < 1 | | 0% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 2 studies (2/-) | 51.7 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 2 studies (2/-) | 51.7 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.66 [0.25, 11.00] | | < 1 | | 0% | 2 studies (2/-) | 30.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.68 [0.10, 4.48] | | < 1 | | 33% | 2 studies (2/-) | 65.4 % | some concern | not evaluable | moderate | non important | - |
| Dry skin TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.23 [0.08, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.26 [0.20, 25.79] | | < 1 | | 0% | 2 studies (2/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.43 [0.11, 18.64] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.92 [0.17, 21.29] | | < 1 | | 0% | 2 studies (2/-) | 29.9 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 1.21 [0.17, 8.64] | | < 1 | | 0% | 2 studies (2/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.08 [0.01, 0.60] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.58 [0.38, 34.02] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.24 [0.05, 1.12] | | < 1 | | 0% | 2 studies (2/-) | 96.5 % | some concern | not evaluable | moderate | non important | - |
